Arcutis Biotherapeutics: Strong Prescription Growth Fuels Buy Rating

In a report released on May 10, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report), with a price target of $17.00.

Uy Ear has given his Buy rating due to a combination of factors related to the performance of Arcutis Biotherapeutics’ products. The report highlights that Zoryve Foam, used for treating Seborrheic Dermatitis, has experienced a significant increase in total prescriptions (TRxs), with a notable week-over-week growth and outperforming the forecasted figures. Furthermore, Zoryve Cream for Plaque Psoriasis has also shown steady prescription growth, demonstrating the products’ strong market acceptance and potential for continued expansion.

Additionally, VTAMA, another product for Plaque Psoriasis, has seen an impressive increase in TRxs and new prescriptions (NRxs), which suggests robust demand. The overall positive trajectory in prescription growth rates for these products, across both new and total prescriptions, indicates a solid performance in the market. These promising trends are key reasons behind Uy Ear’s confidence in the stock, leading to the Buy rating for Arcutis Biotherapeutics.

Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Ear has an average return of 4.5% and a 38.67% success rate on recommended stocks.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Arcutis Biotherapeutics (ARQT) Company Description:

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.